Title
Accumulation of porphyrins in plasma and tissues of dogs after δ-aminolevulinic acid administration: Implications for photodynamic therapy
Date Issued
01 January 1996
Access level
metadata only access
Resource Type
journal article
Author(s)
Cirugía (División de Urología), Estados Unidos
Publisher(s)
Karger
Abstract
Protoporphyrin accumulates in tissues after administration of δ-aminolevulinic acid, and can be used as a photosensitizer for photodynamic therapy. To determine the distribution of porphyrins in a large animal model after administration of this porphyrin precursor, δ-aminolevulinic acid was administered to anesthetized dogs (100 mg/kg body weight intravenously) and porphyrin concentrations were measured in tissues (liver, pancreas, prostate, bladder, muscle and skin), plasma and urine for 6-10 h. Porphyrins increased markedly (up to 50-fold) in plasma within 1 h, were still markedly increased at 8 h, and consisted mostly of coproporphyrin III and protoporphyrin. Tissue porphyrin concentrations increased more slowly, were highest in liver, pancreas and prostate 7-10 h after δ-aminolevulinic acid administration, and were predominantly protoporphyrin. Maximum porphyrin concentrations in liver were 3- and 4-fold higher than in pancreas and prostate, respectively. Urinary δ-aminolevulinic acid excretion increased and was greatest 2-4 h after dosing; urinary porphobilinogen and porphyrins increased more gradually and remained increased up to at least 8 h. Coproporphyrin III was the predominant porphyrin in urine at all times, but hepta-, hexa- and pentacarboxyl porphyrins increased proportionally after administration of δ-aminolevulinic acid. These results indicate that porphyrins accumulate in plasma as well as tissues and urine after administration of δ-aminolevulinic acid, and may contribute to tumor necrosis during photodynamic therapy. © 1996 S. Karger AG, Basel.
Start page
362
End page
370
Volume
52
Issue
6
Language
English
OCDE Knowledge area
Oncología
Subjects
Scopus EID
2-s2.0-0029824659
PubMed ID
Source
Pharmacology
ISSN of the container
0031-7012
Sponsor(s)
National Cancer Institute R44CA060225
Sources of information:
Directorio de Producción Científica
Scopus